R.E. Port Estimating Individual Pretreatment Levels Of A Pharmacologic Response Variable
|
M. Audran(1) , F. Bressolle (2), R. Gareau (3) and R. Gomeni (4) A Population Pharmacodynamics Model Of Recombinant Human Erythropoietin In Athletes
|
Janet R. Wade Presentation Of Population Analyses For Regulatory Submissions
|
Farkad Ezzet & Jeffrey Eisele Inter-Occasion Variation In The Bioavailability Of Benflumetol (An Anti Malarial Drug)
|
P. Girard, L.B. Sheiner A Population Markov Model For Analyzing Dose History
|
Pascal Maire, Roger W. Jelliffe, Xavier Barbaut, Nathalie Bleyzac, Bruno Charpiat, Christine Pivot, Eliane Vermeulen, Pierre Ducrozet, Marie-Aude Confesson, Alain Laffont, Individualized Drug Therapy And Population Modeling
|
Mats O. Karlsson1, Tarja Naukkarinen1,2 and Hans Lennernds1 A Population PK/PD Model For The Anti-Parkinsonian Triple Therapy: Levodopa (Ld), Dopadecarboxylase (Ddc) Inhibitor And Catechol-O-Methyl Transferase (Comt) Inhibitor
|
E. Niclas Jonsson and Mats O. Karlsson XPose - An S-Plus Based Model Building Aid For Population Analysis With Nonmem
|
France Mentre, Alain Mallet Optimal Design In Population Pharmacokinetics
|
Willi Weber, Lutz Harnisch, Christian Rokitta, Jonathan Collins, H.-Juergen Roethig Leflunomide Populationpharmacokinetics And Its Interaction With Activated Charcoal/Cholestyramine
|
Stuart Beal, Ph.D. Simulating PK/PD Trials
|
Stuart Beal, Ph.D. A Preview of NONMEM Version V
|
C.Pobel* - E.Chatelut+ - B.Tranchand x - J.N. Parola* - S.Demare* Neural Network Prediction Of Dose And PP Parameters Values From A Population Approach Point Of View: Some Examples And Comments
|
M. Tod and J.M. Rocchisani Comparison Of ED, EID, API And Bayesian-API Criteria For The Robust Optimisation Of Sampling Times In Pharmacokinetics.
|